Claris Lifesciences posts revenue growth of 25 per cent for quarter ended December 31, 2014
EBITDA grew by 95 per cent
Claris Lifesciences announced its quarterly un-audited financial results for the quarter ended December 31, 2014 at its board meeting held at its registered office in Ahmedabad.
The key financial highlights of the consolidated financials of Claris Lifesciences are shown in the table below.
| Rs. in Million | ||||||||
|
Particulars
|
Q4CY14
|
Q3CY14
|
Growth
|
Q4CY13
|
Growth
|
*CY2014
|
**CY2013
|
Growth
|
| Net Income |
2,094
|
1,789
|
17%
|
1675
|
25%
|
7,144
|
7,112
|
0.4%
|
| EBITDA |
734
|
515
|
43%
|
377
|
95%
|
2045
|
2100
|
– 3.0%
|
| EBITDA% |
35%
|
29%
|
22%
|
29%
|
30%
|
|||
| PAT |
*898
|
204
|
340%
|
178
|
404%
|
*1,390
|
844
|
65%
|
| PAT% |
43%
|
11%
|
11%
|
19%
|
12%
|
|||
|
* Includes pass through sales of COL
|
||||||||
|
** Includes the Infusion Business transferred to COL
|
||||||||
|
# PAT of Q4CY14 includes a onetime reversal of differed
tax liability of Rs. 518 mn due to the slump sale to CIL |
||||||||
The total revenue grew by 25 per cent over the same quarter last year and 17 per cent as compared to the previous quarter of 2014. Year-on-year the total revenue grew by 0.4 per cent in 2014, in 2013 number include the infusion business revenues with was transferred to COL in August 2013 hence these numbers are not comparable.
The EBITDA grew by 95 per cent over the same quarter last year and by 43 per cent as compared to the previous quarter of 2014. The EBTIDA for Q4CY14 includes a onetime income of Rs 116 million. The EBITDA saw de-growth of three per cent year on year, but since the 2013 numbers included the EBITDA from the infusion business transferred to Claris Otsuka, these numbers are not comparable.
The EBITDA margins for Q4CY14 and CY2014 stood at 35 per cent and 29 per cent respectively. The PAT grew by 404 per cent over the same quarter last year and by 340 per cent as compared to the previous quarter of 2014. Year on year, PAT grew by 65 per cent. The PAT margins for Q4CY14 and CY2014 stood at 43 per cent and 19 per cent respectively.
In the speciality injectable business, the net sales for CY2014 stood at Rs 4056 million, which has grown by approximately 62 per cent as compared to CY2013 as per management estimates. EBITDA has grown by nine per cent over the previous quarter. The full year EBITDA of the speciality injectable business stood at Rs 1494 million or 37 per cent of the net sales.
The US has been the key growth driver this year, with sales having grown by 113 per cent in Q2 vs Q1 and by 54 per cent in Q3 vs Q2. The US sales grew by 14 per cent in the fourth quarter as compared to the third quarter.
EP News Bureau – Mumbai
Comments are closed.